Oral JAK inhibitors offered atopic dermatitis patients rapid itch relief in pill form, arriving alongside the injectable biologics. Cibinqo (abrocitinib) is the JAK1-selective entrant.
Abrocitinib is a selective JAK1 inhibitor that interrupts signaling from multiple itch and inflammation cytokines at once, producing faster symptom relief than antibody therapies typically achieve. The once-daily tablet is approved for refractory moderate-to-severe atopic dermatitis when other systemic therapies have not worked.
Cibinqo carries the JAK class boxed warning for serious infections, mortality, malignancy, thrombosis, and major cardiovascular events, which confines it to later-line use. It has since expanded into adolescents, and the class safety label remains the dominant factor shaping its position against biologics.
